Sarah Correia, PA
Medical · Lavonia, GANPI 1801148283
Payments from drug & device makers
Across 133 payments — averaging $15.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$544
- Novo Nordisk$374
- Pfizer$173
- Lilly USA, LLC$159
- GSK$141
- Abbott$101
- plus $507 from 17 others
What the payments were for
- Food & beverage$1,988100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $544 |
| Novo Nordisk | 20 | $374 |
| Pfizer | 10 | $173 |
| Lilly USA, LLC | 11 | $159 |
| GSK | 8 | $141 |
| Abbott | 5 | $101 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Amgen | 3 | $56 |
| Boehringer Ingelheim | 2 | $45 |
| Lundbeck LLC | 2 | $41 |
| Dexcom, Inc. | 2 | $36 |
| Mylan Specialty L.p. | 2 | $34 |
| Biogen | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| AstraZeneca | 2 | $27 |
| Johnson & Johnson | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Shield Therapeutics Inc | 1 | $23 |
| Corium, LLC | 1 | $21 |
| Exact Sciences | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$1,998 in reported general payments places this provider in the 65th percentile of 950 medical providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $106,125 |
| MounjaroTirzepatide | 51 | $68,610 |
| EliquisApixaban | 51 | $58,901 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $46,631 |
| FarxigaDapagliflozin Propanediol | 45 | $32,941 |
| XareltoRivaroxaban | 36 | $27,846 |
| JanuviaSitagliptin Phosphate | 29 | $26,131 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $19,648 |
| JardianceEmpagliflozin | 29 | $19,342 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $16,135 |
| LinzessLinaclotide | 13 | $10,161 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $10,075 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $6,423 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,655 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $374 | $106,12580 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix | $141 | $70,01298 claims |
| Lilly USA, LLCMounjaro | $159 | $68,61051 claims |
| PfizerEliquis | $173 | $58,90151 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat | $45 | $35,07263 claims |
| AstraZenecaFarxiga | $27 | $32,94145 claims |
| Johnson & JohnsonXarelto | $26 | $27,84636 claims |
| AbbVieLinzess | $544 | $10,16113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 950 medical providers in Georgia.
Other medical in Lavonia
- Meredith StatonLavonia$14K
- Tomas ChaoWoodstock$1.9M
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Lisa WeissCanton$283K
- Laura BushFayetteville$146K
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Felicia HoffmanRoswell$114K
- Sally BrumbillLithia Springs$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.